The Quantellect read.As of Nov 19, 2026, 4 active firms cover Carlsmed, Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $17.00 to $24.00, a moderate spread. The average target of $19.50 sits 13% above the current $17.33. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.35 next quarter toward $-1.56 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$19.50
+12.5% upside
Average target across 4 active firms as of Nov 19, 2026 vs $17.33 current
Highest Target$24.00
Average Target$19.50
Lowest Target$17.00
Detailed analyst forecasts for CARL
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate CARL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CARL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.35
Range $-0.35 – $-0.35 · 1 analysts · +33% YoY
Next period, 1 analysts expect Carlsmed, Inc. to earn $-0.35 a share (range $-0.35 – $-0.35), versus $-0.26 a year earlier. Full-year consensus is $-1.51, growing to $-1.56 the year after.
REVENUE · NEXT QUARTER
$24.6M
Range $24.2M – $24.8M · 1 analysts · +52% YoY
Revenue is expected to reach $24.6M (range $24.2M – $24.8M), +52.4% year-over-year. Full-year consensus is $79.3M, rising to $111.9M next year.
Top analysts covering Carlsmed, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CARL.
#1
Ryan Zimmerman
BTIG · Rank #212
Buy
$24.00+38.5% to target
Overall win rate
37%
+ Follow
#2
David Saxon
Needham · Rank #426
Buy
$17.00-1.9% to target
Overall win rate
32%
+ Follow
#3
Richard Newitter
Truist Securities · Rank #532
Buy
$20.00+15.4% to target
Overall win rate
30%
+ Follow
#4
Matt O'Brien
Piper Sandler · Rank #561
Buy
$18.00+3.9% to target
Overall win rate
25%
+ Follow
#5
David Roman
Goldman Sachs
Buy
$16.00-7.7% to target
Coverage
—
+ Follow
CARL stock forecast FAQ
What is CARL's average 12-month price target?+
The 4 active firms with a live target average $19.50 for Carlsmed, Inc. over the next 12 months, ranging from a $24.00 high to a $17.00 low, as of Nov 19, 2026.
Is CARL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CARL?+
The Street-high target is $24.00 (BTIG), and the Street-low is $17.00 (Needham). The average of all 4 active-firm targets is $19.50.
How many active Wall Street firms cover CARL?+
4 active firms have a recognized rating on Carlsmed, Inc. as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CARL?+
Among analysts who currently cover CARL, Ryan Zimmerman of BTIG has the strongest overall Quantellect track record (Rank #212). Their current call is Buy with a $24.00 target.
What is Carlsmed, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.35 per share (range $-0.35 – $-0.35) across 1 analysts. Full-year EPS is projected at $-1.51, rising to $-1.56 the following year.
How much revenue is Carlsmed, Inc. expected to report next quarter?+
Consensus revenue is $24.6M (range $24.2M – $24.8M). Full-year revenue is projected at $79.3M, growing to $111.9M next year.
Have analysts been upgrading or downgrading CARL lately?+
As of Nov 19, 2026, 4 of 4 active firms rate CARL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CARL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.